Oragenics (OGEN) Cash & Equivalents (2010 - 2026)

Oragenics (OGEN) has 17 years of Cash & Equivalents data on file, last reported at $6.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 78.31% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (up 78.31% YoY) and the FY2025 annual result came in at $4.4 million, up 408.73% from the prior year.
• Cash & Equivalents improved to $6.1 million in Q1 2026, from $4.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $21.4 million in Q1 2022 to a low of $864840.0 in Q4 2024.
• A 5-year average of $7.3 million and a median of $5.8 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents slumped 79.17% — and 2025, when it soared 408.73%.
• Tracing OGEN's Cash & Equivalents over 5 years: stood at $11.4 million in 2022, then plunged by 69.51% to $3.5 million in 2023, then slumped by 75.17% to $864840.0 in 2024, then soared by 408.73% to $4.4 million in 2025, then soared by 38.64% to $6.1 million in 2026.
• The last three Cash & Equivalents figures came in at $6.1 million (Q1 2026), $4.4 million (Q4 2025), and $11.4 million (Q3 2025), per Business Quant data.